Best Practice & Research in Clinical Rheumatology最新文献_第9页

Index 索引

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI: 10.1016/j.berh.2023.101921

引用次数: 0

To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question 2023年，轴性脊柱关节炎的生物修饰抗风湿药该减量还是不该减量？这是一个问题

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI: 10.1016/j.berh.2023.101869

Zuzanna Lukasik , Philippe Carron , Casper Webers

引用次数: 0

Challenges in the diagnosis of axial spondyloarthritis 轴性脊柱关节炎的诊断难题

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI: 10.1016/j.berh.2023.101871

Floris A. van Gaalen , Martin Rudwaleit

引用次数: 0

Diagnostic delay in axial spondylarthritis: A lost battle? 轴性脊椎关节炎的诊断延误：一场失败的战斗？

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI: 10.1016/j.berh.2023.101870

Rosemarie Barnett , Karl Gaffney , Raj Sengupta

{"title":"Diagnostic delay in axial spondylarthritis: A lost battle?","authors":"Rosemarie Barnett , Karl Gaffney , Raj Sengupta","doi":"10.1016/j.berh.2023.101870","DOIUrl":"10.1016/j.berh.2023.101870","url":null,"abstract":"<div><p>Diagnostic delay in axial spondylarthritis (axSpA) remains an unacceptable worldwide problem; with evidence suggesting significant detrimental impact both clinically on the individual, and economically on society. There is therefore, a need for global action across various healthcare professions that come into contact with patients living, and suffering, with undiagnosed axSpA. Recent estimates of the median diagnostic delay suggest that globally, individuals with axSpA wait between 2 and 6 years for a diagnosis – revealing a clear benchmark for improvement. This timespan presents a window of opportunity for earlier diagnosis and intervention, which will likely improve patient outcomes. This review describes the current diagnostic delay as estimated across countries and over time, before presenting evidence from published strategies that may be implemented to improve this delay across primary and secondary care, including for specialties treating extra-musculoskeletal manifestations of axSpA (ophthalmology, gastroenterology, dermatology). Ongoing campaigns tackling delayed diagnosis in axSpA are also highlighted.</p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 3","pages":"Article 101870"},"PeriodicalIF":5.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521694223000566/pdfft?md5=2708121be5c9d07090c7a3a4dc4c8d3a&pid=1-s2.0-S1521694223000566-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10492441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy & neonatal outcomes in spondyloarthritis 脊柱关节炎的妊娠和新生儿预后

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-09-01 DOI: 10.1016/j.berh.2023.101868

Sinead Maguire , Anna Molto

引用次数: 0

Pain in osteoarthritis from a symptom to a disease 骨关节炎的疼痛从症状到疾病。

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI: 10.1016/j.berh.2023.101825

Serge Perrot , Trouvin Anne-Priscille

{"title":"Pain in osteoarthritis from a symptom to a disease","authors":"Serge Perrot , Trouvin Anne-Priscille","doi":"10.1016/j.berh.2023.101825","DOIUrl":"10.1016/j.berh.2023.101825","url":null,"abstract":"<div><p>Pain is the most frequent symptom of osteoarthritis<span> (OA), occurring much more commonly than stiffness or disability. Classically, OA-related pain has been considered to be a nociceptive pain condition and an alarm signal correlated to the intensity of joint degradation.</span></p><p><span>However, OA-related pain is a specific disease, with a complex pathophysiology, including neuropathic peripheral and central abnormalities, together with local inflammation involving all joint structures. Clinical findings emphasize that it is not a stable and linear condition, that pain experience is poorly correlated to structural modifications, and that the quality of pain in OA is important to consider, aside from its intensity. OA-related pain is modulated by many factors, including the individual patient's psychological and </span>genetic factors<span><span>, as well as the theoretical role of meteorological influences. Recent findings have improved our knowledge about the central mechanisms of OA pain, especially in persistent cases. A specific questionnaire on OA pain is currently being developed to assess more precisely the patient's experience and target specific pain mechanisms. In conclusion, OA-related pain should be analyzed specifically aside from OA, taking into account the complexity of OA pain as a disease, distinguishing different OA pain phenotypes, to guide more precisely analgesic </span>treatment and OA global management.</span></p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 2","pages":"Article 101825"},"PeriodicalIF":5.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The role of imaging in osteoarthritis 成像在骨关节炎中的作用。

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI: 10.1016/j.berh.2023.101866

Eun Hae Park , Jan Fritz

{"title":"The role of imaging in osteoarthritis","authors":"Eun Hae Park , Jan Fritz","doi":"10.1016/j.berh.2023.101866","DOIUrl":"10.1016/j.berh.2023.101866","url":null,"abstract":"<div><p><span>Osteoarthritis<span> is a complex whole-organ disorder that involves molecular, anatomic, and physiologic derangement. Advances in imaging techniques<span> have expanded the role of imaging in evaluating osteoarthritis and functional changes. Radiography, magnetic resonance imaging, computed tomography<span> (CT), and ultrasonography are commonly used imaging modalities, each with advantages and limitations in evaluating osteoarthritis. Radiography comprehensively analyses alignment and osseous features, while MRI provides detailed information about cartilage damage, </span></span></span></span>bone marrow edema<span>, synovitis<span>, and soft tissue abnormalities. Compositional imaging derives quantitative data for detecting cartilage and tendon degeneration before structural damage occurs. Ultrasonography permits real-time scanning and dynamic joint evaluation, whereas CT is useful for assessing final osseous detail. Imaging plays an essential role in the diagnosis, management, and research of osteoarthritis. The use of imaging can help differentiate osteoarthritis from other diseases with similar symptoms, and recent advances in deep learning have made the acquisition, management, and interpretation of imaging data more efficient and accurate. Imaging is useful in monitoring and predicting the prognosis of osteoarthritis, expanding our understanding of its pathophysiology. Ultimately, this enables early detection and personalized medicine for patients with osteoarthritis. This article reviews the current state of imaging in osteoarthritis, focusing on the strengths and limitations of various imaging modalities, and introduces advanced techniques, including deep learning, applied in clinical practice.</span></span></p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 2","pages":"Article 101866"},"PeriodicalIF":5.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10494578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is new in pharmacological treatment for osteoarthritis? 骨关节炎的药物治疗有何新进展？

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI: 10.1016/j.berh.2023.101841

Halise Hande Gezer , Andrew Ostor

引用次数: 0

Biomarkers for osteoarthritis: Current status and future prospects 骨关节炎的生物标志物：现状与前景。

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI: 10.1016/j.berh.2023.101852

Ali Mobasheri , Christian S. Thudium , Anne-Christine Bay-Jensen , Tazio Maleitzke , Sven Geissler , Georg N. Duda , Tobias Winkler

{"title":"Biomarkers for osteoarthritis: Current status and future prospects","authors":"Ali Mobasheri , Christian S. Thudium , Anne-Christine Bay-Jensen , Tazio Maleitzke , Sven Geissler , Georg N. Duda , Tobias Winkler","doi":"10.1016/j.berh.2023.101852","DOIUrl":"10.1016/j.berh.2023.101852","url":null,"abstract":"<div><p>Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational drugs. We discuss how biomarkers, specifically soluble ones, have a long path to go before reaching clinical standards of care. We also discuss how biomarkers can help in phenotyping and subtyping to achieve enhanced stratification and move toward better-designed clinical trials. We also describe how biomarkers can be used for molecular endotyping and for determining the clinical outcomes of investigational cell-based therapies. Biomarkers have the potential to be developed as surrogate end points in clinical trials and help private-public consortia and the biotechnology and pharmaceutical industries develop more effective and targeted personalized treatments and enhance clinical care for patients with OA.</p></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"37 2","pages":"Article 101852"},"PeriodicalIF":5.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521694223000384/pdfft?md5=1b5ed7f5b7c4f44b66381d1ba9c0667f&pid=1-s2.0-S1521694223000384-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10071278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regenerative methods in osteoarthritis 骨关节炎的再生方法。

IF 5.2 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2023-06-01 DOI: 10.1016/j.berh.2023.101824

Nilay Sahin , Hilal Yesil

引用次数: 0